雾化吸入沙丁胺醇联合布地奈德治疗毛细支气管炎患儿的临床效果

Clinical effect of aerosol inhalation of Salbutamol combined with Budesonide in the treatment of children with bronchiolitis

目的探讨雾化吸入沙丁胺醇联合布地奈德治疗毛细支气管炎患儿的临床效果。方法选取2020年1月至2022年12月于三原县医院就诊的70例毛细支气管炎患儿作为研究对象,按照随机数字表法分为对照组(35例)与观察组(35例)。对照组采用雾化吸入沙丁胺醇,观察组采用雾化吸入沙丁胺醇联合布地奈德。比较两组临床症状消失时间、肺功能及症状评分。结果观察组平喘时间、呼吸复常时间、肺部啰音消失时间及止咳时间均短于对照组(P<0.05)。治疗后,观察组第1秒用力呼气容积与用力肺活量比值、最大自主通气量、最大呼气中期流量及呼气流量峰值均高于对照组(P<0.05)。治疗后,观察组喘憋、呼吸困难、缺氧、呼气喉鸣、咳嗽评分均低于对照组(P<0.05)。结论雾化吸入沙丁胺醇联合布地奈德治疗毛细支气管炎患儿可有效缓解临床症状、改善肺功能,值得临床推广。

Objective To investigate the clinical effect of aerosol inhalation of Salbutamol combined with Budesonide in the treatment of children with bronchiolitis.Methods A total of 70 children with bronchiolitis who were treated in Sanyuan County Hospital from January 2020 to December 2022 were selected as the research objects.According to the random number table method,they were divided into the control group(35 cases)and the observation group(35 cases).The control group received aerosol inhalation of Salbutamol,and the observation group received aerosol inhalation of Salbutamol combined with Budesonide.The disappearance time of clinical symptoms,pulmonary function and symptom scores were compared between the two groups.Results The time of relieving asthma,respiratory recovery time,rales disappearance time and cough relief time in the observation group was shorter than that in the control group(P<0.05).After treatment,forced expiratory volume in one second/forced vital capacity,maximal voluntary ventilation,maximal mid-expiratory flow and peak expiratory flow in the observation group were higher than those in the control group(P<0.05).After treatment,the scores of dyspnea,difficulty in breathing,hypoxia,expiratory laryngeal stridor and cough in the observation group were lower than those in the control group(P<0.05).Conclusion Aerosol inhalation of Salbutamol combined with Budesonide in the treatment of children with bronchiolitis can effectively alleviate clinical symptoms and improve lung function,which is worthy of clinical promotion.